07.11.2012 • News

Hospira Posts Quarterly Profit Vs Year-Ago Loss

Hospira on Wednesday posted a net profit for the third quarter compared with a year-earlier loss as sales rose slightly, and backed its outlook for the full year.

Net earnings were $1.2 million, or 1 cent per share, versus a net loss of $88.9 million, or 54 cents per share, in the 2011 quarter.

Excluding items, earnings were 47 Cents per share. On that basis, analysts on average were expecting earnings of 45 cents.

Sales rose 1.8% to $994.0 million from $976.7 million a year before.

Hospira, a maker of specialty injectable pharmaceuticals and drug pumps, said it continues to expect 2012 net sales to show a fall of 1% to a rise of 2%, excluding the impact of foreign currency.

It forecast full-year earnings per share, excluding items, of $2.00.

 

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.